Gintemetostat showed promising activity in heavily pretreated, triple-class refractory multiple myeloma, including high-risk t(4;14) patients. The phase 1 study reported a tolerable safety profile, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback